Core Viewpoint - The company aims to transform from a traditional pharmaceutical manufacturer to a digital-driven enterprise, aligning with the digital revolution and enhancing its business model for high-quality development [1] Group 1: Digital Transformation Strategy - The company has initiated a digital transformation strategy since August 2023 to adapt to industry changes and policy shifts, establishing a solid foundation for high-quality growth [1] - The company reported a total revenue of 3.63 billion yuan in the past year, a decrease of 4.44% year-on-year, while the pharmaceutical manufacturing segment saw a revenue increase of 4.35% to 1.93 billion yuan [2] - The company has established a collaborative system involving production, supply, testing, sales, and research, leveraging data as a new engine for business [2][3] Group 2: Research and Development Enhancements - The company is shifting its R&D approach from solely relying on in-house development to incorporating commissioned research and market-purchased patents, supported by a comprehensive R&D information database [3] - Currently, the company has five innovative drugs in development, with one in clinical stages and two in pharmaceutical research stages, aiming to transition from a hundred billion market to a trillion market [3] Group 3: Production and Efficiency Improvements - The company has reduced the average procurement cycle for raw materials and packaging by 3 days and 5 days respectively, while improving inspection timeliness by 44% and shortening inspection periods by 43% [3] - The company has implemented AI-assisted processes to enhance production and sales efficiency, resulting in a 90% increase in overall production efficiency for its subsidiary [7] Group 4: Digital Infrastructure and AI Integration - The company has developed a digital platform that has been recognized in the "Digital New Infrastructure" project list in Hunan Province, indicating its commitment to digital transformation [4] - The introduction of AI assistants has streamlined business processes, reducing overall process nodes by over 30% and saving time costs by more than 25% [6] - The marketing AI assistant has significantly aided marketing personnel, contributing to the addition of 344,600 customers and solidifying over 25,000 customers in the company's direct sales model [6][7]
千金药业向“智”求质,打造医药工业生态圈